Spero Therapeutics
168 articles with Spero Therapeutics
-
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
3/6/2023
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
-
Spero Therapeutics to Present at Upcoming March 2023 Investor Conferences
2/28/2023
Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43rd Annual Healthcare Conference.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 28, 2023
2/28/2023
Spero Therapeutics, Inc. announced that on February 22, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 180,000 restricted stock unit awards to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2023
1/31/2023
Spero Therapeutics, Inc. announced that on January 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 16,000 restricted stock unit awards to two new employees under the Spero Therapeutics, Inc.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 22, 2022
12/22/2022
Spero Therapeutics, Inc. announced that on December 19, 2022, the Compensation Committee of Spero’s Board of Directors approved a grant of 155,000 restricted stock unit awards to one new employee under the Spero Therapeutics, Inc.
-
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
11/22/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero) today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5th Annual Evercore ISI HealthCONx Conference.
-
Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update
11/14/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
11/8/2022
Spero Therapeutics, Inc. announced the closing of its previously announced exclusive license agreement with GlaxoSmithKline Intellectual Property Limited for tebipenem HBr, an investigational drug being developed as the potentially first oral carbapenem antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis, caused by certain bacteria.
-
Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
11/7/2022
Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results.
-
Spero Therapeutics to Present Data at IDWeek 2022
10/19/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced data presentations for 7 abstracts accepted at the Infectious Disease Society of America (IDSA) IDWeek™ 2022, taking place from October 19 – 23, 2022 in Washington, DC.
-
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
10/3/2022
Spero Therapeutics, Inc. today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.
-
Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr.
-
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
9/22/2022
GSK and Spero Therapeutics, Inc. announced they have entered into an exclusive license agreement for Spero’s late-stage antibiotic asset, tebipenem HBr.
-
Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
9/15/2022
Spero Therapeutics, Inc. announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer.
-
Spero Therapeutics to Present at Upcoming September 2022 Investor Conference
9/7/2022
Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 24th Annual H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022.
-
Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
9/6/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the U.S. Food and Drug Administration (FDA), discussing steps required for resubmission of the New Drug Application (NDA) for tebipenem HBr for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
-
Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
8/10/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Spero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
8/9/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Wednesday, August 10, 2022 at 4:30 p.m. ET to report its second quarter 2022 financial results and provide an update on its business and pipeline.
-
Spero Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration for its complicated urinary tract infection therapy, tebipenem HBr oral tablets.
-
Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
6/27/2022
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis.